Advanced search
Publication Cover
Cancer Management and Research Volume 4, 2012 - Issue
Submit an article Journal homepage
70
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis

Akshara Richhariya1 Amgen Inc, Global Health Economics, Thousand Oaks, CA, USACorrespondence[email protected]
,
Yi Qian2 Amgen Inc, Global Biostatistical Sciences, Thousand Oaks, CA, USA
,
Yufan Zhao2 Amgen Inc, Global Biostatistical Sciences, Thousand Oaks, CA, USA
&
Karen Chung1 Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA
Pages 55-60 | Published online: 22 Feb 2012

References

  • ColemanREBisphosphonates: clinical experienceOncologist20049 Suppl 4142715459426
  • JamesNDBloomfieldDLuscombeCThe changing pattern of management for hormone-refractory, metastatic prostate cancerProstate Cancer Prostatic Dis20069322122916801939
  • JanjanNBone metastases: approaches to managementSemin Oncol2001284 Suppl 11283411544573
  • ColemanREClinical features of metastatic bone disease and risk of skeletal morbidityClin Cancer Res20061220 Pt 26243s6249s17062708
  • SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
  • Zometa® (zoledronic acid) [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2008
  • DesHarnaisCLBajwaKMarkleJPTimbieJWZackerCSchulmanKAA microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone diseaseSupport Care Cancer20019754555111680835
  • DranitsarisGCastelLDBaladiJFSchulmanKAZoledronic acid versus pamidronate as palliative therapy in cancer patients: a Canadian time and motion analysisJ Oncol Pharm Prac2001712733
  • BerensonJRHillnerBEKyleRAAmerican Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myelomaJ Clin Oncol200220173719373612202673
  • HillnerBEIngleJNBerensonJRAmerican Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert PanelJ Clin Oncol20001861378139110715310
  • HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol200321214042405712963702
  • YabroffKRWarrenJLKnopfKDavisWWBrownMLEstimating patient time costs associated with colorectal cancer careMed Care200543764064815970778
  • Barrett-LeePBloomfieldDDoughertyLAn audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital settingCurr Med Res Opin20072371575158217559749
  • SchivazappaCBaldiniECortesiEDauriaGRoliaFBertoPCost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion studyRecenti Prog Med2007981121517345874
  • WardleyABodyJJNearyMA time-in-motion study of oral ibandronate versus IV zoledronic acid for treatment of metastatic bone disease in breast cancer patientsJ Clin Oncol200523Suppl 16123
  • OglesbyASherifBOdomDLeahyMQianYTime and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone diseaseCommunity Oncol2009611494505
  • FletcherRWFletcherSWClinical epidemiologyThe essentials4th edBaltimoreLippincott Williams & Wilkins2005

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.